Market Place
Sourcing Support
Ardelyx Shares Data On XPHOZAH® At Kidney Week
24 Oct 2024 //
GLOBENEWSWIRE
Ardelyx Presents Data Supporting Xphozah In Chronic Kidney Disease
15 Oct 2024 //
GLOBENEWSWIRE
Ardelyx To Participate At Cantor Global Healthcare Conference
05 Sep 2024 //
GLOBENEWSWIRE
Ardelyx Publishes XPHOZAH® Trial Summaries In Medical Journal
31 Jul 2024 //
GLOBENEWSWIRE
Ardelyx sues US health department over kidney disease drug
18 Jul 2024 //
PRESS RELEASE
Ardelyx Presents IBSRELA IBS-C Data At DDW 2024
21 May 2024 //
GLOBENEWSWIRE
Ardelyx Presents Additional XPHOZAH Data At NKF 2024
16 May 2024 //
GLOBENEWSWIRE
Ardelyx To Present IBSRELA Data At Digestive Disease Week 2024
07 May 2024 //
GLOBENEWSWIRE
Ardelyx Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Ardelyx: XPHOZAH Data In Kidney Disease At NKF 2024 Meeting
01 May 2024 //
GLOBENEWSWIRE
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA
15 Nov 2023 //
GLOBENEWSWIRE
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA
23 Oct 2023 //
GLOBENEWSWIRE
US FDA approves Ardelyx`s kidney disease-related drug
18 Oct 2023 //
REUTERS
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia
13 Oct 2023 //
GLOBENEWSWIRE
Ardelyx Shares Preliminary Data on Use of IBSRELA in Pediatric IBS-C Patients
04 Oct 2023 //
GLOBENEWSWIRE
Ardelyx Announces Publication of Positive Results from Trial of Tenapanor
28 Sep 2023 //
GLOBENEWSWIRE
Tenapanor for Hyperphosphatemia Approved in Japan
25 Sep 2023 //
GLOBENEWSWIRE
Ardelyx Showcased Data on Efficacy of IBSRELA for IBS-C at GHAPP 2023
11 Sep 2023 //
GLOBENEWSWIRE
Ardelyx Announces Acceptance of NDA for Tenapanor for Hyperphosphatemia
13 Jul 2023 //
GLOBENEWSWIRE
Ardelyx Announces FDA Acceptance of its NDA of XPHOZAH (tenapanor)
17 May 2023 //
GLOBENEWSWIRE
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELAÂ
01 May 2023 //
GLOBENEWSWIRE
Ardelyx Resubmits New Drug Application to USFDA for XPHOZAH® (tenapanor)
18 Apr 2023 //
GLOBENEWSWIRE
FDA Grants Appeal for Ardelyx`s XPHOZAH® (tenapanor)
30 Dec 2022 //
PR NEWSWIRE
Ardelyx Provides Update on FDA Appeal for XPHOZAH for the Serum Phosphorus
16 Dec 2022 //
PRNEWSWIRE
Ardelyx’s CKD Drug Clears FDA Adcomm Hurdle with 9-4 Vote
18 Nov 2022 //
BIOSPACE
FDA Advisory Committee to Discuss XPHOZAH for the Control of Serum Phosphorus
17 Nov 2022 //
PRESS RELEASE
Ardelyx Presents Data Analyses at Kidney Week 2022 for the Relevance of XPHOZAH
03 Nov 2022 //
PRNEWSWIRE
Ardelyx & Kyowa, Announces Submission of NDA for Tenapanor for Hyperphosphatemia
31 Oct 2022 //
PRNEWSWIRE
Ardelyx Presents Data at DDW 2022 on IBSRELA for IBS-C in Adults
24 May 2022 //
PRNEWSWIRE
Ardelyx`s last ditch tenapanor appeal successful
26 Apr 2022 //
FIERCEPHARMA
CRL appeal lands Ardelyx an FDA adcomm meeting for embattled CKD drug
25 Apr 2022 //
ENDPTS
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
11 Apr 2022 //
PRNEWSWIRE
Ardelyx tanks after FDA flags problems with tenapanor filing in CKD
19 Jul 2021 //
HCPLIVE
Ardelyx & Kyowa Kirin Highlight New Data Supporting the Clinical and Efficacy
23 Oct 2020 //
PRNEWSWIRE
US FDA accepts Ardelyx’s NDA of tenapanor fr control of serum phosphorus
16 Sep 2020 //
PHARMABIZ
Ardelyx Announces FDA Acceptance for its New Drug Application of Tenapanor
15 Sep 2020 //
PRNEWSWIRE
Ardelyx Announces Submission of New Drug Application U.S. FDA for Tenapanor
30 Jun 2020 //
PRNEWSWIRE
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Ph4
15 Jun 2020 //
PRNEWSWIRE
Ardelyx`s kidney disease drug hits goal in phase 3, teeing it up for FDA filing
03 Dec 2019 //
FIERCE BIOTECH
Ardelyx bags its first FDA OK for IBS, setting up a showdown Allergan, Ironwood
13 Sep 2019 //
ENDPTS
Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market
13 Sep 2019 //
BIOSPACE
Ardelyx`s lead drug tenapanor scores in second hyperphosphatemia study, shares leap
04 Sep 2019 //
ENDPTS
Ardelyx Announces Peer-Reviewed Publication of Positive Ph3 Results Tenapanor
08 Mar 2019 //
PR NEWSWIRE
Ardelyx Announces FDA Acceptance of NDA for Tenapanor for IBS-C
15 Nov 2018 //
PR NEWSWIRE
Ardelyx Presents Data Demonstrating Synergy between Tenapanor & Sevelamer
26 Oct 2018 //
PR NEWSWIRE
